Rachel Chase

Rachel Chase is the co-founder and CEO of Zennea Technologies, a company that seeks to treat sleep apnea with a proprietary medical device. After researching obstructive sleep apnea and chronic snoring, Rachel and her co-founders developed a device to treat the conditions. The device, called ZENS, uses neuro-stimulation technology that externally activates cranial nerves to contract the main dilator muscles of the tongue and reduce upper airway restrictions. It is under clinical trials and would be the first medical device approved by the FDA for use when a CPAP machine would not be prescribed. Rachel hopes to deliver on a comfortable, scientifically-backed method to treat dangerous sleep conditions.